Acute myeloid leukaemia
RecruitingStudy of Pivekimab Sunirine Combined with Venetoclax and Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy
Study of Pivekimab Sunirine Combined with Venetoclax and Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy
- Disease:Acute myeloid leukaemia
- Substances:AzacitidinePivekimab Sunirine+1
Spain- Participants:18–64 years · 65+ years
- Substances:Azacitidine
- Sponsor:AbbVie Deutschland GmbH & Co. KG











